PHILADELPHIA – Researchers from the Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) found that cancer patients who continued to smoke after their diagnosis were significantly more likely to receive treatment for tobacco use when “nudges” to provide tobacco treatment were directed at clinicians through the electronic health record. The findings strengthen the case for using behavioral economics, or targeting predictable patterns in human decision-making to overcome barriers to changes in behavior, to improve outcomes for patients treated for cancer.
The findings were recently published online by the Journal of Clinical Oncology.
More than 50% of patients who smoke prior to their cancer diagnosis continue to smoke after they are diagnosed. This can worsen quality of life and accelerate tumor growth. Routine, evidence-based tobacco use treatment (TUT) – usually involving a referral to a smoking cessation clinic for counseling and potentially using medication to help address tobacco use – reduces the risk of death caused by cancer and other health issues. Despite its benefits, only about half of cancer centers identify patient tobacco use and even fewer engage patients directly in adopting a TUT strategy.
To help increase the use of TUT among cancer patients, researchers wanted to explore the use of strategies informed by behavioral economics to improve TUT uptake among patients and help clinicians improve their willingness to engage in TUT for their patients.
“Oncologists are faced with the challenge of responding to each patient’s individual cancer, so we wanted to see if we could develop a strategy for making their lives as easy as possible by providing simple, timely nudges to help patients engage in tobacco use treatment options,” said first author Brian Jenssen, MD, a researcher and primary care pediatrician with the Division of General Pediatrics at CHOP, a faculty member with PolicyLab and Clinical Futures at CHOP, a senior fellow at the Leonard Davis Institute of the University of Pennsylvania, and a member of the Abramson Cancer Center’s Tobacco and Environmental Carcinogenesis Program. “Clinicians can help their patients find ways of improving their health by helping them quit smoking in a nonjudgmental way.”
In this study, conducted between June 2021 and July 2022, the researchers implemented a randomized clinical trial across 11 sites in the Penn Medicine Abramson Cancer Center (ACC) network. The research team designed and delivered electronic health record-based “nudges” – brief messages intended to remind clinicians and their patients to integrate tobacco treatment into their care plan – in four different combinations: patient only, clinician only, patient and clinician, and usual care with no nudges. These nudges were designed to counteract mental biases that work against TUT, such as concerns about the safety of tobacco treatments versus their potential benefits, and the potential distraction from medical treatment. In total, 246 ACC clinicians were randomized in 95 clusters involving 2,146 eligible cancer patients who smoked while receiving cancer care.
The clinician nudge led to a significant increase in implementation of TUT compared with usual care (35.6% vs. 13.5%). Patient nudges did not impact implementation of TUT, suggesting that clinical staff are more effective targets to collaborate with their patients to adopt TUT strategies and that there is a need to continue to explore ways to improve patient-facing methods to increase TUT engagement.
“This study shows that a behavioral economics ‘nudge’ strategy can increase tobacco use treatment in the oncology setting, which we hope will help more patients with cancer control their tobacco dependence and enjoy better cancer care outcomes,” said senior author Frank T. Leone, MD, director of the Comprehensive Smoking Treatment Program at Penn Medicine, a professor of Pulmonary Medicine in the Perelman School of Medicine, and a member of the Tobacco and Environmental Carcinogenesis Program at the ACC. “We look forward to continuing to build on this research and further increase engagement with tobacco use treatment in the oncology setting.”
This study was supported by National Cancer Institute grant (P50 CA244690), led by principal investigators Rinad S. Beidas, PhD, now at Northwestern University, and Justin Bekelman, MD, and Robert Schnoll, PhD, both at Penn.
Jenssen et al, “A Cluster Randomized Pragmatic Clinical Trial Testing Behavioral Economic Implementation Strategies to Improve Tobacco Treatment for Cancer Patients Who Smoke.” J Clin Oncol. Online July 19, 2023. DOI: 10.1200/ JCO.23.00355.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.